维普中文期刊产品整合服务
768篇 您的检索式:作者名="Lam S M"
    题名 作者 年代 出处 被引量
12018加拿大心境障碍与焦虑障碍治疗协作组/国际双相障碍学会指南:双相障碍的管理显示文摘加拿大心境障碍与焦虑障碍治疗协作组(Canadian Network for Mood and Anxiety Treatments,CANMAT)曾于2005年发布了第1版双相障碍管理指南,并分别于2007、2009和2013年对该指南进行了更新,其中最近的2次更新是与国际双相障碍学会(International Society for Bipolar Disorders,ISBD)合作完成。2018版CANMAT/ISBD双相障碍治疗指南(以下简称指南)反映了自2005年首版指南发表以来本领域取得的重大进展,包括疾病诊断与疾病管理的更新以及药物治疗与心理治疗的近期研究进展。这些前沿进展中综合考虑了循证证据的级别,并基于治疗疗效、临床实践经验、安全性、耐受性和药物导致的转相风险等,对一线、二线及三线治疗方案进行了简明而清晰的推荐。本指南中新增内容涵盖了双相Ⅰ型障碍(BD-Ⅰ)的躁狂发作急性期、抑郁发作急性期和双相障碍维持期的一线及二线治疗推荐等级划分。这种对治疗推荐等级的划分综合考虑了治疗方法对双相障碍不同时相的影响,将进一步帮助临床医生做出基于循证证据的治疗决策。锂盐、喹硫平、双丙戊酸盐、阿塞那平、阿立哌唑、帕利哌酮、利培酮和卡利拉嗪单药或联合使用被推荐为躁狂发作急性期的一线治疗选择。BD-Ⅰ抑郁期的一线治疗选择包括喹硫平、鲁拉西酮、锂盐、拉莫三嗪单药,鲁拉西酮联合锂盐或双丙戊酸盐或拉莫三嗪辅助治疗。尽管急性期治疗有效的药物通常应继续用于BD-Ⅰ的维持期治疗,但也存在一些特殊情况(例如抗抑郁药)。现有数据表明,锂盐、喹硫平、双丙戊酸盐、拉莫三嗪、阿塞那平和阿立哌唑单药或联合治疗应被视为维持治疗的初始或更换治疗方案时的一线选择。除了探讨BD-Ⅰ的相关问题外,本指南中还对双相Ⅱ型障碍(BD-Ⅱ)的临床管理进行了系统回顾并给予治疗推荐,同时针对特殊人群也有相关推荐,如处于各个生殖周期的女性、儿童、青少年和老年人。此外,本指南中还讨论了特定精神疾病及共病(如物质滥用、焦虑障碍和代谢性疾病)的影响。最后,本指南中概述了安全性和药物监测的相关问题。CANMAT/ISBD工作组希望本指南能够成为全球临床医生的实用工具。Lakshmi N Yatham Sidney H Kennedy Sagar V Parikh Ayal Sehaffer David J Bond Benicio N Frey Verinder Sharma Benjamin I Goldstein Soham Rej Serge Beaulieu Martin Alda Glenda MaeQueen Roumen V Milev Arun Ravindran Claire O'Donovan Diane Mclntosh Raymond W Lam Gustavo Vazquez Flavio Kapczinski Roger S Melntyre Jan Kozicky Shigenobu Kanba Beny Lafer Trisha Suppes Joseph R Calabrese Eduard Vieta Gin Malhi Robert M Post Michael Berk 胡晨(译) 王刚(译) 2019中华精神科杂志2019,52,1:25
2WONCA研究论文摘要汇编——慢性阻塞性肺疾病对亚太地区的影响:基于亚洲人群的EPIC调查显示文摘背景慢性阻塞性肺疾病(COPD)是一种慢性、进行性呼吸减弱的临床病症,主要临床表现为不完全可逆性气流受限。在亚太地区,关于COPD患病率的研究较多,但关于COPD影响的研究较少,本研究旨在对COPD的现患病率及其对亚太地区的影响进行综合阐述。方法 2012年2月1日—5月16日,在亚太地区的9个区域进行人群调查。共有112 300个家庭接受调查,从中抽取符合本研究纳入标准(≥40岁;确诊为COPD、慢性支气管炎或肺气肿,或伴有慢性支气管炎症状)的居民69 279例,其中确诊为COPD的居民为4 289例。采用结构式调查问卷,通过面对面采访或电话随访的形式收集居民的相关资料,最终纳入患者1 841例。结果估算COPD总患病率为6.2%,其中19.1%为重症。调查前的12个月内,近一半患者(46.0%)的病情加重,其中19.0%的患者因病情加重而入院治疗。关于COPD对工作的影响,23.0%的患者表示无法工作,42.0%的患者认为该病限制了工作或活动能力。20.0%服用处方药的患者不知晓自身服用药物的名称;44.0%的患者在调查前12个月内服用过常见口服皮质类固醇处方,而吸入器的使用率(25.0%)较低。仅有37.0%的患者进行了肺功能检查,但89.0%接受检测的患者不知晓检查结果。结论亚太地区的COPD患病率较高,因患病带来的社会经济负担较大。COPD管理能力提升空间较大,患者和医生的疾病相关教育有待加强。Lim1 S Chi-Leung Lam D M AR 2015中国全科医学2015,18,28:20
3Elevated basal intestinal mucosal cytokine levels in asymptomatic first-degree relatives of patients with Crohn's disease显示文摘AIM To determine levels of cytokines incolonic mucosa of asymptomatic first degreerelatives of Crohn’s disease patients.METHODS Cytokines(Interleukin(IL)1-Beta,IL-2,IL-5 and IL-8)were measured using ELISAin biopsy samples of normal looking colonicmucosa of first degree relatives of Crohn’sdisease patients(n = 9)and from normalcontrols(n = 10)with no family history ofCrohn’s disease.RESULTS Asymptomatic first degree relativesof patients with Crohn’s disease had significantlyhigher levels of basal intestinal mucosalcytokines(IL-2,IL-5 and IL-8)than normalcontrols.Whether these increased cytokinelevels serve as phenotypic markers for a geneticpredisposition to developing Crohns diseaselater on,or whether they indicate early(pre-clinical)damage has yet to be further defined.CONCLUSION Asymptomatic first degreerelatives of Crohn’s disease patients have higherlevels of cytokines in their normal-lookingintestinal mucosa compared to normal controls,This supports the hypothesis that increasedcytokines may be a cause or an early event inthe inflammatory cascade of Crohns disease andare not merely a result of the inflammatoryprocess.Indaram AVK Nandi S Weissman S Lam S Bailey B Blumstein M Greenberg R Bank S 2000World Journal of Gastroenterology2000,6,1:8
4Secure Group Communications Using Key Graphs显示文摘Wong C Gouda M Lam S 0,,:2
5Soluble E-cadherin is a valid prognostic marker in gastric carcinoma显示文摘Chan A O Lam S K Chu K M 2001Gut2001,48,6:2
6Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure显示文摘Ip M S Lam B Chan L Y 2000Am J Respir Crit Care Med2000,162,6:2
7显示文摘Lam S W Chiang K Lim T M 2005Appl Catal B2005,55,2:1
8Apoptosis and caspases after ischemia-reperfusion injury in rat retina显示文摘Lam T T Abler A S Tso M O 1999Invest Ophthalmol Vis Sci1999,40,5:1
9Inhibition of cyclooxygenase-2 by ro-fecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice显示文摘Yao M Kargman S Lam EC 2003Cancer Res2003,63,3:1
10Drug the rapy for small-cell lung cancer(SCLC)-new molecular strategies fol the rapy显示文摘Bruck I W M Lam pert S 2008Pneum oiogie2008,62,1:1
11Soluble endoglincontributes to the pathogenesis of preeclampsia显示文摘Venkatesha S Toporsian M Lam C 2006Nat Med2006,12,:1
12Learning Nonlinear Multi- regression Networks Based on Evolutionary Computation 显示文摘Leung K S Wong M L Lam W 2002IEEE Transaction on Systems Man and Cybernetics Part B2002,32,:1
13Relationship of gabbro and pillow lavas in the Lupar Formation, West Sarawak: implications for the interpretation of the Lubok Antu M lange and the Lupar Line显示文摘Haile N S Lam S K Banda R M 1994Bulletin of the Geological Society of Malaysia1994,36,:1
14The Drosophila nuclear receptor E75 contains heme and is gas responsive 显示文摘Reinking J Lam M M S Pardee K 2005Cell2005,122,2:1
15Organizational Citizenship Behavior in Workgroups: A Team Cultural Perspective 显示文摘LAI Y M J LAM W L LAM S K S 2013Journal of Organizational Behavior2013,,34:1
16Identificationand characterization of a new degradation product ofIrgarol 1051 in mercuric chloride-catalyzed hydrolysisreaction and in coastal waters显示文摘Lam K H Lam M H W Lam P K S 2004Marine PollutionBulletin2004,49,:1
17A new type of synthetic peptide library for identifying ligand -binding activity 显示文摘LAM K S SALMON S E HERSH E M 1999Nature1999,354,6348:1
18Illumination invariant face recognition显示文摘LIU D H LAM K M SHEN L S 2005Pattern Recognition2005,38,:1
19Soluble endoglin contributes to the pathogenesis of preeclampsia (vol 12, pg 642, 2006)显示文摘Venkatesha S Toporsian M Lam C 2006Nat Med2006,12,7:1
20Soluble endoglin contributes to thep athogenesis of preeclampsia显示文摘Venkatesha S Toporsian M Lam C 2006Nat Med2006,12,6:1
返回顶部 每页显示:
共39页 首页 上一页 第1页 下一页 末页 /39 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费